Neuronetics, Inc. (STIM) Current Ratio
- Current ratio · latest quarter: Value 1.88×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.88× | Current assets / current liabilities. $53.23M ÷ $28.31M ≈ 1.88× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 53.23M USD | Assets, Current |
| Current obligations | 28.31M USD | Liabilities, Current |
| Cash and equivalents | 19.20M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 15.96M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 5.50M USD | Inventory, Net |
| Payables | 12.42M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $53.23M | $28.31M | $19.20M | (m) | $15.96M | $5.50M | $12.42M | (m) | 1.88× |
| 2026-03-31 | $47.17M | $28.29M | $13.21M | (m) | $15.81M | $4.71M | $11.43M | (m) | 1.67× |
| 2025-12-31 | $61.55M | $30.52M | $28.13M | (m) | $16.47M | $4.33M | $10.74M | (m) | 2.02× |
| 2025-09-30 | $64.89M | $28.94M | $27.97M | (m) | $18.69M | $4.32M | $11.57M | (m) | 2.24× |
| 2025-06-30 | $56.14M | $27.80M | $10.97M | (m) | $26.12M | $4.94M | $9.72M | (m) | 2.02× |
| 2025-03-31 | $60.67M | $24.84M | $20.22M | (m) | $26.20M | $4.07M | $8.48M | (m) | 2.44× |
| 2024-12-31 | $58.12M | $31.27M | $18.46M | (m) | $23.36M | $4.25M | $11.08M | (m) | 1.86× |
| 2024-09-30 | $19.64M | $37.46M | $368.51K | (m) | $12.63M | (m) | $10.56M | (m) | 0.52× |
| 2024-06-30 | $75.51M | $29.26M | $42.64M | (m) | $17.14M | $6.14M | $4.10M | $13.61M | 2.58× |
| 2024-03-31 | $81.86M | $14.50M | $47.73M | (m) | $17.50M | $6.69M | $2.98M | (m) | 5.65× |
| 2023-12-31 | $93.79M | $19.81M | $59.68M | (m) | $15.78M | $8.09M | $4.75M | (m) | 4.73× |
| 2023-09-30 | $71.01M | $15.34M | $35.85M | (m) | $15.02M | $9.74M | $2.82M | (m) | 4.63× |
| 2023-06-30 | $77.68M | $15.03M | $45.91M | (m) | $13.14M | $8.87M | $4.14M | (m) | 5.17× |
| 2023-03-31 | $81.11M | $15.13M | $55.44M | (m) | $9.45M | $9.14M | $4.97M | (m) | 5.36× |
| 2022-12-31 | $98.77M | $33.20M | $70.34M | (m) | $13.59M | $8.90M | $2.43M | $13.13M | 2.98× |
| 2022-09-30 | $101.10M | $25.14M | $73.70M | (m) | $11.96M | $8.57M | $2.35M | $8.75M | 4.02× |
| 2022-06-30 | $95.08M | $18.94M | $70.93M | (m) | $11.39M | $7.18M | $2.35M | $4.38M | 5.02× |
| 2022-03-31 | $103.11M | $13.18M | $80.84M | (m) | $8.25M | $7.55M | $2.76M | (m) | 7.82× |
| 2021-12-31 | $115.33M | $15.70M | $94.14M | (m) | $7.71M | $6.56M | $4.30M | (m) | 7.34× |
| 2021-09-30 | $119.45M | $47.81M | $99.43M | (m) | $7.75M | $5.36M | $3.31M | $35.10M | 2.50× |
| 2021-06-30 | $134.88M | $11.58M | $115.78M | (m) | $9.00M | $5.39M | $2.42M | (m) | 11.65× |
| 2021-03-31 | $138.95M | $10.91M | $121.28M | (m) | $6.96M | $5.40M | $3.24M | (m) | 12.74× |
| 2020-12-31 | $65.01M | $13.68M | $48.96M | (m) | $7.17M | $3.72M | $3.75M | (m) | 4.75× |
| 2020-09-30 | $65.20M | $45.78M | $50.72M | (m) | $5.56M | $3.78M | $2.37M | $34.54M | 1.42× |
| 2020-06-30 | $67.21M | $45.35M | $54.00M | (m) | $6.64M | $3.33M | $2.32M | $34.37M | 1.48× |
| 2020-03-31 | $76.43M | $12.39M | $63.65M | (m) | $6.25M | $2.88M | $3.61M | (m) | 6.17× |
| 2019-12-31 | $88.45M | $27.69M | $75.71M | (m) | $6.57M | $2.77M | $4.63M | $11.25M | 3.19× |
| 2019-09-30 | $95.91M | $22.00M | $82.37M | (m) | $7.55M | $2.92M | $4.11M | $7.50M | 4.36× |
| 2019-06-30 | $101.30M | $16.61M | $89.64M | (m) | $7.56M | $2.55M | $3.66M | $3.75M | 6.10× |
| 2019-03-31 | $106.04M | $11.86M | $96.15M | (m) | $5.67M | $2.41M | $2.59M | (m) | 8.94× |
| 2018-12-31 | $114.47M | $13.56M | $104.58M | (m) | $5.62M | $2.43M | $3.76M | (m) | 8.44× |
| 2018-09-30 | $116.74M | $15.30M | $106.76M | (m) | $5.28M | $2.61M | $2.10M | $5.00M | 7.63× |
| 2018-06-30 | $26.00M | $14.85M | $14.54M | (m) | $4.72M | $2.44M | $2.93M | $2.50M | 1.75× |
| 2017-12-31 | $37.01M | $11.99M | $29.15M | (m) | $4.27M | $2.47M | $2.51M | (m) | 3.09× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Profound Medical Corp. (PROF) | $0.206B | -7.37 | |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Lucid Diagnostics Inc. (LUCD) | United States | $0.170B | |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| KORU Medical Systems, Inc. (KRMD) | United States | $0.151B | -106.78 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |